Drug resistance among new TB cases in some Russian regions

Testov, Vadim; Пузанов, В. А.; Marina, Yakimova; Punga, V. V.

doi:10.1183/13993003.congress-2015.pa2717

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A symposium on tuberculosis in the Russian Federation noted the problems in containing drug resistance. Results of the implementation of routine DST in three oblasts noted a high rate of MDR-TB [ 43 ]. Delays in DST were important in the extended use of first-line drugs and, although MDR-TB treatment failure was only significant if the delay was >24 months, the cost of further transmission to the community was thought to be high, as proved by B atyrshina [ 45 ].…”

Section: Tuberculosismentioning

confidence: 99%

The best of respiratory infections from the 2015 European Respiratory Society International Congress

Polverino

Bothamley

Goletti³

et al. 2016

ERJ Open Res

View full text Add to dashboard Cite

The breadth and quality of scientific presentations on clinical and translational research into respiratory infections at the 2015 European Respiratory Society (ERS) International Congress in Amsterdam, the Netherlands, establishes this area as one of the leadings fields in pulmonology. The host–pathogen relationship in chronic obstructive pulmonary disease, and the impact of comorbidities and chronic treatment on clinical outcomes in patients with pneumonia were studied. Various communications were dedicated to bronchiectasis and, in particular, to different prognostic and clinical aspects of this disease, including chronic infection with Pseudomonas and inhaled antibiotic therapy. Recent data from the World Health Organization showed that Europe has the highest number of multidrug-resistant tuberculosis cases and the poorest countries have the least access to suitable treatments. Latent tuberculosis and different screening programmes were also discussed with particular attention to risk factors such as HIV infection and diabetes. Several biomarkers were proposed to distinguish between active tuberculosis and latent infection. Major treatment trials were discussed (REMOX, RIFQUIN and STREAM). The possibility of once-weekly treatment in the continuation phase (RIAQUIN) was especially exciting. The continuing rise of Mycobacterium abscessus as a significant pathogen was noted. This article reviews some of the best contributions from the Respiratory Infections Assembly to the 2015 ERS International Congress.

show abstract

Section: Tuberculosismentioning

confidence: 99%